Could a middle-aged, non-diabetic, non-hypertensive patient who suddenly collapsed and died after receiving an intravenous test dose of ceftriaxone have experienced an anaphylactic reaction?

Yes, this was almost certainly an anaphylactic reaction to ceftriaxone.

A middle-aged patient who suddenly collapsed and died immediately after receiving intravenous ceftriaxone test dose most likely experienced fatal anaphylaxis—this is a well-documented, though rare, complication of ceftriaxone administration that can occur even on first exposure and without prior drug allergy history. 1

Why This Presentation is Consistent with Anaphylaxis

The clinical scenario you describe—sudden collapse and death within minutes of IV ceftriaxone administration—matches the classic presentation of severe, rapidly progressive anaphylaxis:

• Timing: Anaphylaxis typically occurs within minutes of exposure to the offending agent 2. The immediate temporal relationship between ceftriaxone administration and collapse is highly suggestive.

• Route of administration: Intravenous administration carries higher risk for severe, rapid-onset anaphylaxis compared to other routes 2. The IV route allows immediate systemic exposure to the allergen.

• Cardiovascular collapse: Anaphylaxis can cause transfer of up to 50% of intravascular fluid into the extravascular space within 10 minutes, leading to hemodynamic collapse that may occur rapidly with little or no cutaneous or respiratory manifestations 2. This explains why a patient can collapse and die without obvious urticaria or wheezing.

Evidence Specific to Ceftriaxone-Induced Anaphylaxis

The FDA drug label explicitly warns that "serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported" with ceftriaxone 1. Postmarketing surveillance has documented "anaphylactic or anaphylactoid reactions" as adverse events 1.

Recent case reports confirm this risk:

• Multiple documented cases of cardiac arrest and asystole occurring within 30 seconds to 1 minute of ceftriaxone administration 3, 4, 5
• Fatal outcomes have been reported even in patients with no known antibiotic allergies 3, 6
• A 2023 analysis from Syria identified 14 fatal cases of ceftriaxone-associated adverse reactions, with most fatalities resulting from immediate anaphylactic reactions following IV or IM administration 6

Critical Pitfall: "Test Dose" Does Not Prevent Anaphylaxis

A common and dangerous misconception is that a "test dose" protects against anaphylaxis—it does not. Anaphylaxis can occur with the first exposure to any dose, including a test dose. The concept of a test dose for antibiotics is not evidence-based and provides false reassurance 7. Even intradermal allergy testing itself has caused fatal anaphylaxis with ceftriaxone 6.

Differential Diagnosis Considerations

While anaphylaxis is most likely, the differential for sudden collapse after IV medication includes:

• Vasovagal reaction: However, this typically presents with bradycardia, pallor, cool skin, and absence of urticaria—not the rapid progression to death 2, 8, 2
• Myocardial infarction or arrhythmia: Possible but less likely given the immediate temporal relationship
• Pulmonary embolism: Would not have such immediate onset after drug administration
• Ceftriaxone-calcium precipitation: Relevant in neonates but causes different pathophysiology 1

The immediate temporal relationship (within seconds to minutes), IV route, and fatal outcome make anaphylaxis the most probable diagnosis.

What Should Have Been Done

According to current guidelines, the management of suspected anaphylaxis requires:

1. Immediate discontinuation of the suspected agent 8
2. Intramuscular epinephrine 0.01 mg/kg (max 0.5 mg) into the vastus lateralis as first-line treatment—this is the single most important intervention 9, 10, 8, 9
3. Activation of emergency response and preparation for advanced resuscitation 9
4. Supine positioning with legs elevated (if hypotensive) 8
5. IV fluid resuscitation for hypotension 8
6. Repeat epinephrine every 5-10 minutes if no response 9, 2

Delay in administering epinephrine is associated with increased risk of fatal outcomes 10, 8. In this case, if epinephrine was not immediately available or administered, this represents a critical systems failure.

Key Clinical Lessons

• Any patient receiving IV medications must have immediate access to epinephrine and resuscitation equipment 2
• Ceftriaxone can cause fatal anaphylaxis even in patients without prior drug allergies 3, 6
• "Test doses" do not prevent anaphylactic reactions and create false security
• Patients should be monitored for at least 30 minutes after any parenteral antibiotic administration, though most severe reactions occur within minutes 2
• No absolute contraindications exist for epinephrine in anaphylaxis—cardiac disease, age, or hypertension are not reasons to withhold it 8, 11